(Q30436143)

19 September 2017

Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? (English)

1 reference

19 September 2017

1 reference

Nicola G Ghazi

1

1 reference

19 September 2017

Tyler Q Kirk

2

1 reference

19 September 2017

Robert M Knape

3

1 reference

19 September 2017

James S Tiedeman

4

1 reference

19 September 2017

Brian P Conway

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

26 April 2010

1 reference

19 September 2017

Clinical Ophthalmology

1 reference

19 September 2017

4

1 reference

19 September 2017

307-314

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 September 2017

start time

1 April 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Inhibitors of ocular neovascularization: promises and potential problems.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Testing intravitreal toxicity of bevacizumab (Avastin).

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Pegaptanib for neovascular age-related macular degeneration

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2861937

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20463798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20463798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20463798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/OPTH.S8598

1 reference

19 September 2017

1 reference

19 September 2017

PubMed publication ID

20463798

1 reference